Ind Swift Ltd has received the DCGI approval for manufacturing and marketing of sustained /modified release tablet of anti-infective Clarithomycin Clarie-SR, the trade name, is sustained release tablet to be taken once a day against the normal dosage form, which is required to be taken twice a day. The Company has already filed the international patent for this drug in the US, Europe, Latin America, Canada and other Asian countries.

In the next five years drugs worth US$ 40 billion goes off patent and the Company is targeting the US$ 5 billions of these drugs which would be open for launch in the modified release form after the patent expiry.